Search Clinical Trials in the European Union

Duration
Visits
Efficacy phase (II)
Intake methods
Benefits
Drugs
Locations
Clinical Specialty
1361-1380 of 1,738 trials

Bipolar Disorder: Low-Dose Aspirin Study

We are investigating whether adding low-dose aspirin to standard treatment helps improve symptoms in patients with bipolar disorder. This study aims to assess both the effectiveness and safety of this approach.

Bipolar Disorder1-2 yearsEfficacy phase (II)Standard MedicinesPartially RemotePsychiatry

Melanoma with Brain Metastases: Immunotherapy Study

We are studying the effects of immunotherapy in melanoma patients with brain metastases who are also receiving steroid treatment. Our goal is to see if this combination improves outcomes compared to standard care.

Malignant Melanoma of Skin1-2 yearsEfficacy phase (II)11-15 visitsPost-Trial Drug AccessNo PlaceboStandard MedicinesNeurologyOncology

Clofarabine for Advanced Urothelial Carcinoma

We are studying the safety and effectiveness of Clofarabine in patients with locally advanced or metastatic urothelial carcinoma. The trial aims to find the highest dose that can be tolerated while assessing how well the treatment works.

Bladder Cancer3-6 monthsSafety phase (I)Efficacy phase (II)6-10 visitsNo PlaceboStandard MedicinesOncology

Diabetic Cardiovascular Autonomic Neuropathy: The FibroCAN Study

We are investigating whether finerenone can help improve heart function and reduce nerve damage in people with type 2 diabetes and early-stage cardiovascular autonomic neuropathy. This study compares the treatment to a placebo to assess its effects.

Diabetic Cardiovascular Autonomic Neuropathy1-2 yearsEfficacy phase (II)6-10 visitsInvestigational MedicinesCost ReimbursementCardiologyEndocrinologyNeurology

Activated T-Cells for Graft vs Host Disease After Stem Cell Transplant

We are testing a new treatment using activated regulatory T-cells in patients shortly after stem cell transplantation. The aim is to see if it can safely reduce the risk and severity of acute graft vs host disease.

LeukaemiaAcute graft versus host disease1-2 yearsSafety phase (I)Efficacy phase (II)6-10 visitsNo PlaceboInvestigational MedicinesHematologyOncology

Advanced Solid Tumors: BMS-986482 Study

We are investigating the safety and dosage of BMS-986482 alone or with other therapies for patients with advanced solid tumors. This study aims to understand how well it works in combination with existing treatments.

Advanced Solid Tumors>2 yearsSafety phase (I)Efficacy phase (II)Post-Trial Drug AccessNo PlaceboInvestigational MedicinesPartially RemoteOncology

Crizotinib for Children with Severe Type 2 Neurofibromatosis

We are studying whether crizotinib can help reduce tumor size in children with severe type 2 neurofibromatosis who are not eligible for surgery or radiotherapy. We will also evaluate the safety of this treatment.

Neurofibromatosis Type 21-2 yearsEfficacy phase (II)16-20 visitsNo PlaceboStandard MedicinesNeurologyOncology

Kidney Transplant in Children: Prolonged-Release Tacrolimus Study

We are studying a new form of tacrolimus for children who have undergone kidney transplantation. The goal is to see if it works as well and is as safe as the current version used.

Caucasian Pediatric Kidney Transplant Recipients1-2 yearsEfficacy phase (II)Confirmation phase (III)No PlaceboStandard MedicinesNephrologyPediatrics

Gastroenteropancreatic and Thoracic Neuroendocrine Tumors: Cabozantinib and Lanreotide Study

We are studying the safety and effectiveness of a new combination treatment for patients with gastroenteropancreatic and thoracic neuroendocrine tumors. This trial aims to find out if this combination can improve treatment outcomes compared to current options.

Gastroenteropancreatic and Thoracic Neuroendocrine TumorEfficacy phase (II)Post-Trial Drug AccessNo PlaceboStandard MedicinesEndocrinologyOncology

Epstein-Barr Virus Diseases: Tabelecleucel Treatment

We are studying a new treatment called tabelecleucel for individuals with Epstein-Barr virus-associated diseases. The goal is to see if it can improve health outcomes compared to current options.

EBV-Related Lymphoproliferative Disorder>2 yearsEfficacy phase (II)≤5 visitsNo PlaceboStandard MedicinesHematologyInfectious DiseasesOncology

Immune-Related Rheumatological Events in Cancer Patients

We are collecting data on how to better diagnose and manage joint and muscle issues caused by cancer treatments. This study involves multiple centers to improve care for patients receiving checkpoint inhibitors.

Cancer (all types)>2 yearsEfficacy phase (II)≤5 visitsNo PlaceboStandard MedicinesCost ReimbursementPartially RemoteOncologyRheumatology

Melanoma Treatment: Vemurafenib, Cobimetinib, and Atezolizumab

We are studying a combination of three medications for patients with high-risk melanoma to see if it helps achieve a complete response. We also want to understand its effects on survival and safety.

High-Risk MelanomaEfficacy phase (II)No PlaceboStandard MedicinesDermatologyOncology

Bronchopulmonary Dysplasia: Stem Cell Treatment for Preterm Infants

We are studying the safety of umbilical cord stem cells in preterm babies with bronchopulmonary dysplasia. This research aims to see if the treatment can help improve their lung health and overall development.

Bronchopulmonary Dysplasia>2 yearsEfficacy phase (II)No PlaceboInvestigational MedicinesPediatricsPulmonology

Cholangiocarcinoma: SIRT and Capecitabine Study

We are evaluating a new treatment combining radiation therapy and chemotherapy for patients with operable intrahepatic cholangiocarcinoma. This study aims to see if this combination helps improve treatment outcomes before surgery.

Intrahepatic Cholangiocarcinoma>2 yearsEfficacy phase (II)No PlaceboStandard MedicinesOncology

Generalized Anxiety Disorder: ITI-1284 Treatment Study

We are evaluating the safety and effectiveness of a new medication, ITI-1284, for people with Generalized Anxiety Disorder who haven't found relief with current treatments. This study compares ITI-1284 to a placebo to see how well it works.

Generalized Anxiety Disorder≤3 monthsEfficacy phase (II)6-10 visitsInvestigational MedicinesPsychiatry

Eosinophilic Esophagitis: EP 104GI Treatment Study

We are testing a new treatment called EP 104GI for adults with eosinophilic esophagitis. The study aims to evaluate its safety and effectiveness in reducing symptoms and improving esophageal health.

Eosinophilic Esophagitis1-2 yearsSafety phase (I)Efficacy phase (II)6-10 visitsNo PlaceboInvestigational MedicinesAllergologyGastroenterology

Sjögren's Syndrome: Stem Cell Treatment for Dry Mouth

We are studying whether injecting stem cells into the salivary glands can improve saliva flow in patients with dry mouth from Sjögren's syndrome. This trial will also assess safety and other effects on saliva quality.

Sjögren's Syndrome≤3 monthsSafety phase (I)Efficacy phase (II)≤5 visitsInvestigational MedicinesOrthopedics and TraumatologyRheumatology

Sublingual Vaccine: Trained Immunity Study

We are investigating whether a new sublingual vaccine can boost the immune system's response in blood cells. This study aims to understand its effects on trained immunity.

Healthy Participants>2 yearsSafety phase (I)Efficacy phase (II)

Endometrial Cancer: New Treatment Combination

We are studying a new combination of a dual mTOR inhibitor and anastrozole for women with metastatic hormone receptor-positive endometrial cancer. The goal is to see if this combination works better than anastrozole alone.

Advanced and Metastatic CancerSafety phase (I)Efficacy phase (II)Gynecology and ObstetricsOncology

Imlifidase for Severe ANCA-associated Vasculitis

We are studying whether imlifidase, combined with standard care, can improve outcomes for patients with severe ANCA-associated vasculitis and pulmonary hemorrhage. The trial will also assess its safety and effects on health markers.

ANCA-Associated Vasculitis3-6 monthsEfficacy phase (II)11-15 visitsNo PlaceboStandard MedicinesPulmonologyRheumatology